Zenas BioPharma(ZBIO)
WALTHAM, MAPharmaceutical
Focus: Zenas BioPharma is a publicly traded immunology-focused biotech company developing immune-based therapies for neurology, immunology, and endocrinology indications. The company is early-stage with minimal revenue ($5M in FY2025) but substantial R&D investment.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
20+2 this month
Stable — net +2 jobs in 30d
9 added, 7 removed. Backfill posture.
Should You Work at Zenas BioPharma?
AI assessmentZenas offers early-stage biotech upside with immunology expertise and Phase 3 clinical catalysts, but carries pre-revenue cash burn risk and limited near-term career stability.
Why Work Here
- Rare disease focus across high-unmet-need indications (MS, IgG4-RD, thyroid eye disease, lupus, AIHA) with potential for accelerated approval pathways
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$5M
Pipeline & Clinical Trials
ZB001 for injection
Healthy VolunteersClinical Trials (1)
NCT05542303A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects
Phase 1Help build intelligence for Zenas BioPharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.